<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592019000200235</article-id>
<article-id pub-id-type="doi">10.19136/hs.a18n2.2918</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Beneficio-riesgo del uso de factor de transferencia (Hebertrans®) en la práctica médica habitual]]></article-title>
<article-title xml:lang="en"><![CDATA[Benefit-risk use of transfer factor (Hebertrans®) in usual medical practice]]></article-title>
<article-title xml:lang="pt"><![CDATA[Risco-benefício do uso de fator de transferência (Hebertrans®) na prática médica habitual]]></article-title>
<article-title xml:lang="fr"><![CDATA[Bénéfice-risque de l'utilisation du facteur de transfert (Hebertrans®) dans la pratique médicale habituelle]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz Barrios]]></surname>
<given-names><![CDATA[María Aida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Furones Mourelle]]></surname>
<given-names><![CDATA[Juan Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Escuela Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Escuela Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>18</volume>
<numero>2</numero>
<fpage>235</fpage>
<lpage>242</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592019000200235&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592019000200235&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592019000200235&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Objetivos: Analizar la relación beneficio-riesgo del FT (Hebertrans®) en la práctica médica.  Método:  Se empleó el enfoque bayesiano para comparar la probabilidad de beneficio (evolución satisfactoria de los pacientes) con la de riesgo (presencia de reacciones adversas durante o después del tratamiento). La información se obtuvo de publicaciones que investigan las reacciones adversas y la evolución clínica de pacientes tratados con Hebertrans®.  Resultados:  Se observó mayor porcentaje de reacciones adversas entre los que evolucionaron de forma no satisfactoria (24,5%), que entre los que evolucionaron bien (12,2%). La diferencia entre beneficio y riesgo favoreció al primero (Factor de Bayes =2,3).  Conclusiones:  El balance beneficio-riesgo por el uso de factor de transferencia, (Hebertrans®), fue a favor del beneficio, pues a pesar que la evolución clínica de los pacientes no es satisfactoria, este medicamento provoca pocas reacciones adversas; las más frecuentes están relacionadas con el sitio de administración y son leves. Sin embargo, son necesarios estudios epidemiológicos controlados para verificar estos resultados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Objectives.  Analyze the benefit-risk ratio of FT (Hebertrans®) in medical practice.  Method:  The Bayesian approach was used to compare the likelihood of benefit (satisfactory evolution of patients) with risk (presence of adverse reactions during or after treatment). The information was obtained from publications investigating adverse reactions and the clinical evolution of patients treated with Hebertrans®.  Results:  A higher percentage of adverse reactions was observed with patients who evolved in an unsatisfactory way (24.5%), than among those who progressed correctly (12.2%). The difference between benefit and risk favored the first (Bayes Factor = 2.3).  Conclusions:  The benefit-risk balance for the use of the transfer factor (Hebertrans®) was in favor of the benefit, despite the fact that the clinical evolution of patients is not satisfactory, this drug causes few adverse reactions; the most frequent are related to the administration site and are mild. However, controlled epidemiological studies are necessary to verify these results.]]></p></abstract>
<abstract abstract-type="short" xml:lang="fr"><p><![CDATA[Résumé :  Objectifs : Analyser le rapport bénéfice-risque de l'utilisation de FT (Hebertrans®) dans la pratique médicale habituelle.  Méthode:  L&#8217;approche bayésienne a été utilisée pour comparer la probabilité d&#8217;avantage (évolution satisfaisante des patients) à risque (présence d'effets indésirables pendant ou après le traitement). L'information a été obtenue à partir de publications qui étudient les effets indésirables et l'évolution clinique des patients traités par Hebertrans®.  Résultats:  Un pourcentage plus élevé d'effets indésirables a été observé chez les patients qui ont évolué de manière peu satisfaisante (24,5%), que chez ceux qui ont évolué correctement (12,2%).La différence entre bénéfice et risque a favorisé le premier (facteur de Bayes = 2,3).  Conclusions:  Le rapport bénéfice-risque pour l'utilisation du facteur de transfert (Hebertrans®) était en faveur du profit, bien que l'évolution clinique des patients n'est pas satisfaisante, ce médicament provoque peu de réactions indésirables; les plus fréquentes sont liées au site d'administration et sont bénignes. Cependant, des études épidémiologiques contrôlées sont nécessaires pour vérifier ces résultats.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Objetivos:  Analisar a relação risco-benefício do FT (Hebertrans®) na prática médica.  Método:  Utilizou-se uma abordagem Bayesiana para comparar a probabilidade de benefício (evolução satisfatória dos doentes) com a de risco (presença de reações adversas durante ou após o tratamento). A informação foi obtida através de publicações que investigam as reações adversas e a evolução clínica dos doentes tratados com Hebertrans®.  Resultados:  Observou-se uma maior percentagem de reações adversas entre aqueles que evoluíram de modo satisfatório (24,5%), e os que evoluíram bem (12,2%). A diferença entre benefício e risco favoreceu o primeiro (Fator Bayes = 2,3).  Conclusões:  A relação risco-benefício para o uso do fator de transferência (Hebertrans®) foi favorável ao benefício, pois apesar de a evolução clínica dos doentes não ser satisfatória, este medicamento provoca poucas reações adversas; as mais frequentes estão relacionadas com o local de administração e são ligeiras. No entanto, são necessários estudos epidemiológicos controlados para confirmar estes resultados.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[factor de transferencia]]></kwd>
<kwd lng="es"><![CDATA[reacciones adversas]]></kwd>
<kwd lng="es"><![CDATA[beneficio-riesgo]]></kwd>
<kwd lng="es"><![CDATA[Farmacoepidemiología]]></kwd>
<kwd lng="en"><![CDATA[transfer factor]]></kwd>
<kwd lng="en"><![CDATA[adverse reactions]]></kwd>
<kwd lng="en"><![CDATA[benefit-risk]]></kwd>
<kwd lng="en"><![CDATA[pharmacoepidemiology]]></kwd>
<kwd lng="fr"><![CDATA[facteur de transfert]]></kwd>
<kwd lng="fr"><![CDATA[réactions indésirables]]></kwd>
<kwd lng="fr"><![CDATA[bénéfice-risque]]></kwd>
<kwd lng="fr"><![CDATA[pharmacoépidémiologie]]></kwd>
<kwd lng="pt"><![CDATA[fator de transferência]]></kwd>
<kwd lng="pt"><![CDATA[reações adversas]]></kwd>
<kwd lng="pt"><![CDATA[risco-benefício]]></kwd>
<kwd lng="pt"><![CDATA[fármaco-epidemiologia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strom]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Kimmel]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Hennessy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Textbook of Pharmacoepidemiology]]></source>
<year>2013</year>
<page-range>3-16</page-range><publisher-loc><![CDATA[Chichester (UK) ]]></publisher-loc>
<publisher-name><![CDATA[John Wiley &amp; Sons Ltd]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Necesidad de la Farmacoepidemiología]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lara]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barbado]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Farmacoepidemiología. Uso racional de medicamentos]]></source>
<year>2010</year>
<page-range>1-14</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Academia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez G]]></surname>
<given-names><![CDATA[Alfonso]]></given-names>
</name>
</person-group>
<source><![CDATA[Normas y Procedimientos del Sistema Cubano de Farmacovigilancia.]]></source>
<year>2012</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[TarragóPortelles]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Gravier Hernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gil del Valle]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La Farmacovigilancia en Cuba y las Infranotificaciones de Reacciones Adversas a los Medicamentos]]></article-title>
<source><![CDATA[HORIZONTE SANITARIO]]></source>
<year>2019</year>
<page-range>7-17</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="book">
<collab>Centro Estatal para el Control de Medicamentos, Equipos y Dispositivos Médicos</collab>
<source><![CDATA[Resumen de las características del producto]]></source>
<year>2013</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<collab>Ministerio de Salud Pública</collab>
<article-title xml:lang=""><![CDATA[Cuadro Básico de medicamentos y productos naturales]]></article-title>
<source><![CDATA[Internet]]></source>
<year>2018</year>
<volume>#093</volume>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Minsap]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calvo Barbado]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado Martínez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Formulario Nacional de Medicamentos]]></source>
<year>2014</year>
<volume>#093</volume>
<page-range>578</page-range><publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mollineda]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Mártínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rabaza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunomoduladores. Respuesta al tratamiento en niños desnutridos menores de un año de edad]]></article-title>
<source><![CDATA[Rev Cubana Pediatr]]></source>
<year>1999</year>
<page-range>191-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inclán]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Parada]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Respuesta clínica e inmunológica en pacientes con déficit de inmunoglobulina A, después del tratamiento con factor de transferencia.]]></article-title>
<source><![CDATA[Rev. Cubana HematolInmunolHemoter]]></source>
<year>1994</year>
<page-range>80-1</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inclán]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[del Valle]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Macías]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factor de transferencia y levamisol. Evaluación clínica e inmunológica en niños con infecciones respiratorias recurrentes. Informe preliminar]]></article-title>
<source><![CDATA[Rev. Cubana HematolInmunolHemoter]]></source>
<year>1991</year>
<page-range>92-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diogene]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Figueras]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Debesa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Laporte]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Cuban experience in focusing pharmaceuticals policy to health population needs: initial results of the National Pharmacoepidemiology Network (1996-2001)]]></article-title>
<source><![CDATA[Pharmacoepidemiology and Drug Safety]]></source>
<year>2003</year>
<page-range>2</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="book">
<collab>Colectivo de autores</collab>
<source><![CDATA[Modelo cubano de la red nacional de farmacoepidemiología. Promoción del uso adecuado de los medicamentos]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Ciudad de La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Academia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Rego]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos adversos asociados al tratamiento con factor de transferencia. Ciudad de La Habana, 2004]]></article-title>
<source><![CDATA[Rev. Cubana Farm]]></source>
<year>2006</year>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Alfonso]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eventos adversos observados después del tratamiento con factor de transferencia.]]></article-title>
<source><![CDATA[Rev. Cubana Salud Pública]]></source>
<year>2012</year>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[BN]]></given-names>
</name>
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Huete]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución clínica de pacientes tratados con factor de transferencia]]></article-title>
<source><![CDATA[Rev Cubana Hematología]]></source>
<year>2004</year>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Furones]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[de la Fuente]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eventos adversos observados años después del tratamiento con factor de transferencia]]></article-title>
<source><![CDATA[Revista Cuba de Salud Pública]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correa Morales]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Barrera Causil]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Introducción a la estadística bayesiana]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Medellín ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Tecnológico Metropolitano]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Armijo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influencia de los factores genéticos y ambientales, la edad y el embarazo sobre la respuesta a los fármacos]]></article-title>
<source><![CDATA[Flórez J, Armijo JA, Mediavilla A. Farmacología Humana. 6ta edición]]></source>
<year>2014</year>
<page-range>121-56</page-range><publisher-loc><![CDATA[Barcelona ]]></publisher-loc>
<publisher-name><![CDATA[Masson-SA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aagaard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Strandell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Melskens]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[PSG]]></given-names>
</name>
<name>
<surname><![CDATA[Holme]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Global Patterns of Adverse Drug Reactions Over a Decade. Analyses of Spontaneous Reports to VigiBase. Drug Saf]]></source>
<year></year>
<page-range>1171-82</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alomar]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors affecting the development of adverse drug reactions]]></article-title>
<source><![CDATA[SaudiPharmaceuticalJournal]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martins Sanches]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes Coelho]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Onofre]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunoestimulantes en la prevención de infecciones respiratorias en la infancia]]></article-title>
<source><![CDATA[Residencia Pediátrica]]></source>
<year>2015</year>
<page-range>128-13</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
